An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma. by Watkins, AJ et al.
An Integrated Genomic and Expression Analysis of 7q
Deletion in Splenic Marginal Zone Lymphoma
A. James Watkins1., Rifat A. Hamoudi1., Naiyan Zeng1, Qingguo Yan1,2, Yuanxue Huang1,
Hongxiang Liu3, Jianzhong Zhang4, Esteban Braggio5, Rafael Fonseca6, Laurence de Leval7,
Peter G. Isaacson8, Andrew Wotherspoon9, Ellen D. McPhail10, Ahmet Dogan10", Ming-Qing Du1,3*"
1Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom, 2 State Key Laboratory of Cancer Biology,
Department of Pathology, Xijing Hospital, Xian, People’s Republic of China, 3Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom,
4Department of Pathology, 306 Hospital, Beijing, People’s Republic of China, 5Comprehensive Cancer Centre, Mayo Clinic in Arizona, Scottsdale, Arizona, United States of
America, 6Division of Hematology, Cancer Center – Oncology, Mayo Clinic in Arizona, Scottsdale, Arizona, United States of America, 7 Institut Universitaire De Pathologie,
Lausanne, Switzerland, 8Department of Histopathology, University College London Hospital, London, United Kingdom, 9Department of Histopathology, Royal Marsden
Hospital, London, United Kingdom, 10Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America
Abstract
Splenic marginal zone lymphoma (SMZL) is an indolent B-cell lymphoproliferative disorder characterised by 7q32 deletion,
but the target genes of this deletion remain unknown. In order to elucidate the genetic target of this deletion, we
performed an integrative analysis of the genetic, epigenetic, transcriptomic and miRNomic data. High resolution array
comparative genomic hybridization of 56 cases of SMZL delineated a minimally deleted region (2.8 Mb) at 7q32, but
showed no evidence of any cryptic homozygous deletion or recurrent breakpoint in this region. Integrated transcriptomic
analysis confirmed significant under-expression of a number of genes in this region in cases of SMZL with deletion, several
of which showed hypermethylation. In addition, a cluster of 8 miRNA in this region showed under-expression in cases with
the deletion, and three (miR-182/96/183) were also significantly under-expressed (P,0.05) in SMZL relative to other
lymphomas. Genomic sequencing of these miRNA and IRF5, a strong candidate gene, did not show any evidence of somatic
mutation in SMZL. These observations provide valuable guidance for further characterisation of 7q deletion.
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Introduction
Splenic marginal zone lymphoma (SMZL) is a rare indolent B-
cell non-Hodgkin’s lymphoma, being less than 2% of lymphoid
malignancies [1], and the genetic basis underlying its develop-
ment is poorly understood. SMZL lacks chromosome transloca-
tion that characterises other low grade B-cell lymphomas.
Approximately, 30% of SMZL are characterised by heterozygous
7q deletion, which is also seen in splenic B-cell lymphoma/
leukaemia unclassifiable but rarely in other lymphoma subtypes
[2–4]. The genes targeted by this 7q deletion remain unknown.
By BAC (bacterial artificial chromosome) array comparative
genomic hybridisation (aCGH), we recently narrowed the
minimally deleted region (MDR) to a 3.04 Mb region at 7q32
[4], which contains over 40 coding genes and a cluster of 6
microRNAs (miR-593, miR-129, the miR-182/96/183 polycis-
tron and miR-335).
The 7q deletion may play an important role in the pathogenesis
of SMZL. To investigate this, we searched for evidence of any
potential tumour suppressor genes in the MDR. The classic
tumour suppressor genes are often inactivated on both alleles by
multiple mechanisms including homozygous deletion, heterozy-
gous deletion and mutation, and transcriptional repression by
promoter methylation. To ascertain the gene or genes targeted by
the 7q deletion in SMZL, we sought evidence of homozygous
deletion by gene resolution array CGH of chromosome 7. We also
assessed the expression of miRNA and coding genes in the MDR
and correlated their expression levels with the 7q deletion status.
For the coding genes, we further correlated their expression with
the methylation status. Finally, genomic sequencing was per-
formed on the miRNA and key candidate genes in the MDR to
search for inactivating mutation.
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Materials and Methods
Case Selection
A total of 95 cases of SMZL were analysed in this study: 35
cases were the subject of a previous oligonucleotide aCGH study
by the Mayo Clinic group [5] and the remaining 60 cases were the
subject of BAC aCGH and interphase FISH (fluorescence in situ
hybridisation) investigation by the Cambridge research group [4].
All were well characterised cases diagnosed on histological
investigation of the splenic specimens by specialist haematopa-
thologists according to the 2008 WHO classification of tumours
haematopoietic and lymphoid tissues (Supplementary Table S1)
[1]. The use of these archival tissues for research was approved by
the local ethics committees. In each of the SMZL cases included in
this study, patient had splenectomy and the genetic and epigenetic
investigations described below were based on the splenic tissue
specimens.
Array Comparative Genomic Hybridization
A total of 56 case of SMZL were investigated by aCGH using
oligonucleotide array platform in this study. A series of 35 SMZL
(including 10 with 7q deletion) were examined using the Agilent
aCGH 244A platform (6.4 Kb resolution) (Agilent Technologies,
Palo Alto, California, USA) by the Mayo Clinic group in a
previous study (http://www.ncbi.nlm.nih.gov/geo/, GSE35278)
[5]. In addition, a customised oligonucleotide array was
constructed (Agilent Technologies), with a 2 Kb resolution
covering the whole chromosome 7q and further overlapping
probes spanning all the miRNA at 7q32, including the miR-29a/
29b1 polycistron. The miR-29a/29b1 polycistron lies distal to the
MDR, but has been shown to be down-regulated in SMZL and
other lymphomas [6], and was therefore also covered by
overlapping probes. A further series of 21 SMZL (including 7
cases with 7q deletion) were investigated using this customised
oligonucleotide array (GSE 21554) by the Cambridge group in this
study.
The oligonucleotide array CGH was carried out essentially
according to the manufacturer’s instructions. Briefly, genomic
DNA was extracted from frozen tissues containing .60% tumour
cells based on histological estimation with the assistance of CD20
and CD3 staining, together with retrospective review of the CGH
profile. DNA (800 ng) was labelled with Cy5 (sample) and Cy3
(mixed normal reference) using the BioPrimeH aCGH Labelling
Kit (Invitrogen). Labelled genomic reactions were cleaned-up with
purification columns (Invitrogen). The labelled DNA was mixed
with Cot-1 DNA (Invitrogen), 106 Blocking Agent and 26 Hi-
RPM Hybridization Buffer (Agilent) and hybridised to the array in
a 60uC oven for 20 hours. Slides were scanned in an Agilent High
Resolution-C scanner. Data was analysed using the Agilent
Feature Extraction Software v10.5 and visualized in Genomic
WorkbenchH Standard Edition (v.5.0.14).
Copy-number abnormalities (CNA) were calculated using the
aberration detection module (ADM)-2 algorithm. Copy number
variations (CNV) were identified and excluded from the analysis
by reference to the database of genetic variation (Build GRCh37,
Feb 2009: http://projects.tcag.ca).
Expression Microarray Analysis
A total of 48 cases of SMZL (including 15 with 7q deletion)
were analysed using the Affymetrix HG-U133 Plus 2.0 platform
(Affymetrix, Santa Clara, California, USA). Arrays were
performed according to the manufacturer’s instructions. Briefly,
RNA was extracted from snap frozen tissues with .60%
tumour cells using the RNeasy extraction kit (Qiagen) and
subjected to DNAse treatment (Turbo DNAse kit, Ambion).
RNA integrity was assessed using an Agilent 2100 Bioanalyzer.
cDNA synthesis was carried out with 2 mg RNA using the
GeneChipH One-Cycle cDNA Synthesis Kit (Affymetrix),
followed by in vitro transcription with biotin-labelled nucleotides
using GeneChipH IVT Labeling Kit. Biotinylated cRNA was
purified and hybridized to the Affymetrix HG-U133 Plus 2.0
chips in a GeneChipH Hybridisation Oven 640 at 45uC for 14
hours. The arrays were then washed and stained using the
Fluidics station 450 system (Affymetrix). The arrays were
scanned using the Affymetrix GeneArrayH Scanner 3000.
Hybridisation and labelling controls were included according
to the manufacturer’s instructions, and quality control analysis
of microarrays was performed to published standards [7–9].
The data have been deposited with GEO (GSE21554,
GSE35348).
Bioinformatic Analysis of Expression Data
Raw gene expression data from Affymetrix.CEL files were
uploaded to Bioconductor where a combined MAS5 and
gcRMA normalization procedure was performed and used to
filter out non-variant probes across all samples as described
previously [9]. The gcRMA normalized data were imported
into Genespring 7.3.1 and log-transformed. Expression levels of
the genes on chromosome 7 were compared between cases of
SMZL with and without 7q deletion by one-way ANOVA test
with Benjamini Hochberg multiple testing correction. Genes
with P,0.05 were considered to be differentially expressed. In
addition, the differentially expressed genes were further filtered
by fold changes to eliminate those with moderate changes
,1.256SD (standard deviation). In house software was written
in R to plot the P value and fold change along the chromosome
7 sequence.
Array Based Epigenetic Methylation Analysis
Epigenetic methylation analysis was performed using the
InfiniumH Human Methylation 27 array (Illumina, San Diego,
California, USA). The array contained 27,568 CpG islands within
the proximal promoter regions of transcription start sites of 14,475
RefSeq genes, including 12,883 well annotated genes (NCBI
CCDS database: Build 36). The methylation array was carried out
in 12 SMZL (6 cases with 7q deletion), 6 follicular lymphomas (FL)
and 6 mantle cell lymphomas (MCL) as per the manufacturer’s
instructions. Briefly, 2 mg genomic DNA extracted from frozen
tissues with .60% tumour cells was bisulphite modified using the
EZ DNA MethylationTM Kit (Zymo Research Corporation).
Bisulphite modified DNA was then amplified using the MSM
master mix (Illumina) and incubated at 37uC for 22 hours.
Amplified DNA was then fragmented and hybridised to
BeadChips in an Illumina Hybridisation Oven at 48uC for 18
hours. Following hybridisation, single base extension of hybridised
DNA using hapten labelled bases was performed. Staining was
then developed using immunochemical stains catalysed by the
haptens, and the arrays washed. The chips were scanned using the
BeadArrayTM Reader (Illumina) and the BeadScanTM software
(Illumina) using the Infinium Methylation Scan setting. The
scanned data was then analysed in GenomeStudioTM (Illumina)
using the Methylation analysis module. The data are available
from GEO (GSE21554).
Bioinformatic Analysis of Methylation Data
The scanned data was spatially normalised to correct for
background noise using the Smethillium algorithm (http://
bioinfo-out.curie.fr/projects/smethillium) within the R environ-
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ment (www.r-project.org) [10]. Where multiple probes targeted
different CpG loci relating to one gene, the probe predicted to
have the greatest influence on gene expression (eg. at a
transcriptional factor binding site, proximity to the promoters)
was selected for analysis.
Quantitative RT-PCR Analysis of miRNA
Total RNA was extracted from frozen tissues of 18 SMZL
including 8 cases with 7q deletion, and 15 other low grade B-cell
lymphomas including 7 FL, 4 MCL and 4 mucosa associated
lymphoid tissue (MALT) lymphomas using the miRNEasyH kit
(Qiagen). In each case, the frozen tissue used for RNA extraction
contained at least 60% of tumour cells. The expression level of
mature miR-593, miR-129, miR-182, miR-96, miR-183, miR-
335, miR-29a, and miR-29b1 and their minor variants was
investigated by qRT-PCR using the Qiagen miScriptH system
(Supplementary Table S2). Briefly, 1 mg of total RNA was reverse
transcribed using the miScriptH RT kit and 500 ng of the cDNA
product was then subjected to quantitative PCR with the
QuantiTectH SYBR Green system (Qiagen) using a BioRad IQ
Light-Cycler. The PCR primers for the major and minor species
of mature miR-593, miR-129, miR-182, miR-96, miR-183, miR-
335, miR-29a, and miR-29b1 are detailed in Table S1. The
reverse primer was a universal primer to a tag added during the
RT step. In each case, the reaction was carried out in triplicate,
and different runs were normalised against a common calibrator
sample. The geometric mean of the expression of RNU6b and
SCARNA17 was used as a reference and expression levels was
calculated by the DDCt method. Statistical analysis of expression
between groups was performed using the Mann-Whitney test, and
correlation of expression of major and minor species and of
miRNA transcribed from the same polycistron using Pearson’s
correlation co-efficient.
Genomic Sequencing of miRNA and Coding Genes
Mutation analysis of miRNA was performed in 60 cases of
SMZL. Primers flanking the predicted primary miRNA (pri-
miRNA) (approximately 100 bp 5¢ and 3¢ of the predicted loop)
were designed for miR-593, miR-129, miR-182, miR-96, miR-
183, miR-335, miR-29a, and miR-29b1 (Table S3) according to
the miRBase database (www.mirbase.org). PCR product was
purified using EXO-Sap-IT (USB) and sequenced using the
BigDyeH Terminator v3.1 Cycle Sequencing kit on an ABI-3730
sequencer (Applied Biosystems). Sequences were aligned using
SeqScapeH v2.5 (Applied Biosystems). The nucleotide alterations
identified were first excluded from known polymorphisms by
searching the dbSNP database (Build 132) (www.ncbi.nlm.nih.
gov/projects/SNP). Where indicated, PCR and sequencing of the
DNA sample from the microdissected normal cells were carried
out to ascertain whether the mutation was a somatic or germline
change. The intact splenic capsule was manually microdissected
under a light microscope as described previously [11] and used as
a source of non-neoplastic DNA.
Similarly, IRF5 was investigated for somatic mutation in SMZL
by PCR and sequencing in 49 cases of SMZL, 28 FL, 8 MCL and
32 DLBCL (Table S4).
Results
High Resolution Array CGH Delineates a Common Region
of Heterozygous Deletion at 7q32
Figure 1 summarised the 7q deletion in SMZL detected by
CGH using a chromosome-7 BAC tile-path array (17 cases) and
the Agilent aCGH 244A array CGH (10 cases) from our previous
studies [4,5]. There was no correlation between 7q deletion and
patient’s survival (Supplementary Table S5). The combined
analyses mapped the MDR to a region of 2.8 Mb (127,287795-
130,078068 Mb, GRCh37), but showed no evidence of homozy-
gous deletion within the MDR. To further investigate the possible
existence of cryptic homozygous deletions that might have been
under-detected by the above BAC tile-path and standard Agilent
oligonucleotide array CGH, we investigated 21 cases of SMZL
including 7 with 7q deletion using a customised oligonucleotide
array with a 2 Kb resolution covering the whole chromosome 7q
and gene resolution in the MDR. Despite this high resolution
coverage, no evidence of cryptic or homozygous deletions of either
miRNA or coding genes was observed in any of the cases
investigated.
Within the MDR, there were 6 miRNA (miR-593, miR-129,
miR-182, miR-96, miR-183, miR-335) with miR-29a/29b1
polycistron distal to the MDR, and 38 potential coding genes
(Table 1).
Under-expression of miRNA of the MDR in SMZL with 7q
Deletion
We first investigated whether the expression of the miRNA
within the 7q32 MDR was impaired by 7q deletion by comparing
their expression between SMZL with (n = 8) and without 7q
deletion (n = 10) using qRT-PCR. In general, 1) there was a
significant correlation between the expression of major and minor
species of the miRNA (P,0.001) and also among the miRNA
transcribed from the same polycistron (p,0.001), indicating good
quality of experimental data; and 2) the expression of mature miR-
593, miR-129, miR-182, miR-96, miR-183, miR-335, miR-29a
and miR-29b1 was consistently reduced in cases with 7q deletion
as compared with those without the deletion (Figure 2 & Figure
S1), albeit not statistically significant with the exception of miR-
29a, most likely due to small number of cases investigated.
It is thus likely that 7q deletion underlies the reduced expression
of these miRNA. Interestingly, the expression of these miRNA was
also different among SMZL, FL, MCL and MALT lymphoma
entities (Figure 2), with SMZL in general showing much lower
expression levels. In particular, miRNA in the miR-182/miR-96/
miR-183 polycistron showed statistically significant under-expres-
sion in SMZL (Figure S1, P,0.05).
Genomic Sequencing of miRNA of the MDR Revealed No
Evidence of Somatic Mutation
To further search for evidence that miRNA may be the
target of 7q deletion in SMZL, we performed PCR and
sequenced the miR-593, miR-129, miR-182, miR-96, miR-183,
miR-335, miR-29a and miR-29b1 genes in 23 cases of SMZL.
This initial screening revealed a SNP, rs76481776 (G to A
substitution at nucleotide position 106), in the primary miR-182
in 5 cases of SMZL but showed no nucleotide alterations in any
of the other primary miRNA investigated. In addition, two
novel SNPs were observed in the 3¢ region distal to the pri-
miR-182 hairpin. Subsequent screening showed the rs76481776
(G106A) variant in 12 (20%) of the 60 SMZL investigated.
There was no association between the rs76481776 substitution
and 7q deletion, or immunoglobulin heavy chain somatic
mutation status. The rs76481776 substitution was also seen
frequently in FL (20%), HCL (13%), MALT lymphoma (13%),
PTCL-NOS (9%), less frequently in CLL (5%), DLBCL (4%)
and MCL (3%), but not in lymphoplasmacytic lymphoma and 3
lymphoma cell lines (Figure S2).
Analyses of 7q Deletion in SMZL
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Under-expression of Coding Genes at 7q32 in SMZL with
7q Deletion
To investigate whether any of the coding genes at 7q32 may be
the target of 7q deletion, we compared the expression of the genes
on chromosome 7 between SMZL with (n = 15) and without 7q
deletion (n = 33) by analysis of the Affymetrix gene expression
profile. In general, the genes on 7q, particularly those within the
MDR, were under-expressed in cases with 7q deletion, in keeping
with the relatively large and heterogeneous regions affected by the
deletion (Figure 1). Within the MDR, there were 38 potential
coding genes, and 37 of them were represented on the U133 Plus
2.0 array (PRRT4 was not represented). Of these 37 genes, 18
(TNPO3, KLHDC10, RBM28, NIPA, SND1, TSGA14, TMEM209,
UBE2H, NRF1, NAG8, ATP6V1F, CALU, AHCYL2, COPG2, HIG2,
TSPAN33, IMPDH1 and IRF5) were significantly under-expressed
in SMZL with 7q deletion in comparison with those without the
deletion (Figure S3, Supplementary Table S6) (P,0.05). In 9
(24%) of these genes, the fold changes were more than
Figure 1. Investigation of 7q deletion in SMZL by array CGH and Affymetrix gene expression analyses. CGH using the chromosome 7
(Ch7) BAC tile-path array, Agilent 244A oligonucleotide array platform and chromosome 7 gene resolution oligonucleotide array maps the MDR to a
2.8 Mb region at 7q32 (Panel A). As shown by Affymetrix gene expression analyses, the genes on 7q, particularly those within the MDR are
significantly under-expressed in SMZL with 7q deletion than those without the deletion. Panel B shows the genes significantly differentially expressed
between SMZL with and without 7q deletion according to P values, while Panel C displays those with further fold change more than 1.256SD
(standard deviation).
doi:10.1371/journal.pone.0044997.g001
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.1.256standard deviation. As a baseline control, only 7 (11.7%)
of the 60 genes on 7p were expressed at levels significantly lower in
cases with 7q deletion than those without the deletion according to
the same criteria.
Integrative Epigenetic and Transcriptomic Analysis of the
Genes within MDR
Transcriptional repression by promoter methylation is one of
the common mechanisms underlying the inactivation of tumour
suppressor genes. To search for potential evidence of gene
inactivation by promoter methylation, we correlated the levels of
promoter methylation and expression of the genes within the
MDR in SMZL. Among the 37 genes which were represented in
both the methylation and Affymetrix expression arrays, CPA4,
OPN1SW, NAG8, LRRC4, CPA5, CPA2, TSGA13, CPA1, C7orf45
and NYD-SP18 consistently showed high levels of methylation but
low gene expression in each of the SMZL with 7 q deletion (Figure
S4). To examine whether this was specific to SMZL, we
investigated FL and MCL, and correlations between high levels
of methylation and low expression of these genes were also found
in these lymphoma entities.
Sequencing of IRF5 in SMZL Reveals Recurrent
Polymorphism but No Evidence of Somatic Mutation
Among the coding genes within the MDR, IRF5, an essential
transcriptional factor activated by TLR signalling, is critical for
antiviral immunity and functions as a tumour suppressor [12]. In
view of the putative role of viral infection in pathogenesis of SMZL
and recent finding of activating mutations in MYD88 (an adaptor
in TLR signalling) in SMZL, we investigated whether IRF5 was
targeted by mutation. By sequencing the coding exons (2–9) of
IRF5, we identified an in-frame deletion polymorphism in exon 6
Table 1. Summary of somatic mutation of the genes of the 7q MDR in human cancer.*
Gene Full name Mutation frequency Nature of mutation Cancer type




Ovarian carcinoma’ primitive neuroestodermal
tumour- medulloblastoma, laryngeal carcinoma
LRRC4 leucine rich repeat containing 4 4/154 2.6% Missense,
inframe deletion
Glioma, breast carcinoma, colon carcinoma,
pancreatic carcinoma
LEP leptin 0/90 0% N/A N/A
RBM28 RNA binding motif protein 28 2/92 2.2% Missense, Ovarian carcinoma
IMPDH1 IMP (inosine 5’-monophosphate)
dehydrogenase 1
5/231 2.2% Missense, Skin melanoma, glioma, lung carcinoma,
Ovarian carcinoma
METTL2A methyltransferase like 2A 2/250 0.8% Missense, Mouth squamous carcinoma, pharyngeal carcinoma
FAM71F1 family with sequence similarity 71,
member F1
2/70 2.8% Missense, nonsense Skin melanoma, mouth squamous carcinoma
CCDC136 2/25 8% Missense, Ovarian carcinoma
FLNC filamin C, gamma 7/142 4.9% Missense, nonsense Skin melanoma, breast carcinoma, primitive
neuroestodermal tumour-medulloblastoma, colon
carcinoma, ovarian carcinoma
KCP kielin/chordin-like protein 0/68 0% N/A N/A
IRF5 interferon regulatory factor 5 0/217 0% N/A N/A
TNPO3 transportin 3 2/219 0.9% Missense, nonsense Skin melanoma, lung carcinoma
ATP6V1F ATPase, H+ transporting, lysosomal
14 kDa, V1 subunit F
1/91 1% Missense, Ovarian carcinoma
TSPAN33 tetraspanin 33 1/91 1% Missense, Ovarian carcinoma
SMO smoothened, frizzled family receptor 32/2436 1.3% Missense,
Inframe insertion
Skin basal cell carcinoma, primitive neuroestodermal
tumour- medulloblastoma, lung carcinoma, colon
carcinoma, glioma, bile duct carcinoma
AHCYL2 adenosylhomocysteinase-like 2 3/71 4.2% Missense, nonsense laryngeal carcinoma, ovarian carcinoma
NRF1 nuclear respiratory factor 1 1/91 1% Missense Ovarian carcinoma
UBE2H ubiquitin-conjugating enzyme E2H 1/217 0.5% N/A N/A
ZC3HC1 (NIPA) zinc finger, C3HC-type containing 1 0/90 0% N/A N/A
KLHDC10 kelch domain containing 10 0/90 0% N/A N/A
TMEM209 transmembrane protein 209 2/92 2.2% Missense, Ovarian carcinoma, colon carcinoma
CPA2 carboxypeptidase A2 (pancreatic) 1/92 1% Missense, Mouth squamous carcinoma
CPA4 carboxypeptidase A4 3/517 0.6% Missense, nonsense laryngeal carcinoma, ovarian carcinoma
CPA5 carboxypeptidase A5 2/93 2.1% Missense, nonsense Ovarian carcinoma
MEST mesoderm specific transcript homolog 2/516 O.6% Missense, nonsense Ovarian carcinoma
TSGA13 testis specific, 13 3/93 3.2% Missense, laryngeal carcinoma, ovarian carcinoma
KLF14 Kruppel-like factor 14 1/91 1% Missense, Mouth squamous carcinoma
*From the COSMIC database (http://www.sanger.ac.uk/genetics/CGP/cosmic/).
doi:10.1371/journal.pone.0044997.t001
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(rs60344245) in 29/49 (59%) of SMZL investigated, with
heterozygous mutation in 14 (28.6%) and homozygous mutation
in 15 (30.6%) (Figure S5). The polymorphism was similarly seen in
FL (18/28 = 64%, heterozygous deletion in 14/28 = 50% and
homozygous deletion in 4/28 = 14.2%), MCL (6/8 = 75%, het-
erozygous deletion in 3/8 = 37.5% and homozygous deletion in 3/
8 = 37.5%) and diffuse large B-cell lymphoma (22/32 = 68%,
heterozygous deletion in 15/32 = 46.8% and homozygous deletion
in 7/32 = 21.9%) (Figure S5). The frequencies of the IRF5
polymorphism in these lymphomas were higher or similar to those
(49%) described in healthy German blood donors [13].
Figure 2. Heatmap illustration of the qRT-PCR of the 6 miRNA (miR-593, miR-129, miR-182, miR-96, miR-183, miR-335) within the
MDR and 2 miRNA (miR-29a/29b1 polycistron) distal to the MDR. The results show that the expression of these mature miRNAs is in general
lower in SMZL with 7q deletion than those without the deletion, although not statistically significant with the exception of miR-29a. *minor miRNA
species, FL: follicular lymphoma; MCL: mantle cell lymphoma; MALT-L: MALT lymphoma.
doi:10.1371/journal.pone.0044997.g002
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Discussion
The Characteristics of 7q Deletion in SMZL
By extensive high-resolution array CGH analyses of a large
cohort of SMZL, the present study mapped the MDR of 7q
deletion in SMZL to a region of 2.8 Mb (127,287795-130,078068
Mb, GRCh37). There are several features associated with the
deletion, which are worth pointing out in considering the
candidate genes targeted by the deletion. First, there was no
evidence of recurrent breakpoints or cryptic deletion, which
might indicate a particular single gene as the target of the
deletion. This finding raises the probability that multiple genes
are targeted by the deletion. Second, there was no evidence of
homozygous deletion at 7q32 in SMZL. Thus, it is unknown
whether the gene targeted by 7q deletion is a classic tumour
suppressor gene and required to be inactivated on both alleles,
and if so, an alternative mechanism of inactivation must be
responsible. Finally, the SMZL with 7q deletion do not constitute
a distinct subgroup as shown by integrated clinicopathological
and gene expression microarray analyses [4,14–16]. This suggests
the possibility of presence of common molecular mechanisms
between SMZL with and without 7q deletion. It is possible that
the gene targeted by 7q deletion is inactivated by somatic
mutation and/or promoter methylation in SMZL lacking the
deletion. Alternatively, the molecular mechanism/cellular path-
way deregulated by the 7q deletion may be similarly altered by
other genetic events in cases without the deletion. Lastly, it is also
possible that the genes targeted by the 7q deletion do not play a
predominant role in the pathogenesis of SMZL, thus not bearing
a major impact on gene expression profiles and clinicopatholog-
ical presentation.
miRNA as Possible Candidate Targets of 7q Deletion in
SMZL
As shown by qRT-PCR, there was a clear trend of under-
expression of all the miRNA within the MDR in SMZL with 7q
deletion as compared with those without the deletion. In
addition, the expression of miR-29a, which was located distal
to the MDR, was significantly reduced in SMZL with 7q deletion
than those without the deletion. Under-expression of miR-29a in
SMZL has also been reported in previous studies [6,17].
Although miR-29 was outside of the MDR, the region of 7q
deletion was considerably heterogeneous and in 33 of the 34 cases
of SMZL with 7q deletion investigated in this study, miR-29 was
within the deleted region. It is thus likely that 7q deletion
underlies the reduced expression of all these miRNAs. Interest-
ingly, the expression of these miRNA, particularly miR-183/96/
182 (which are transcribed from the same polycistron, P,0.05)
was significant lower in SMZL than FL, MCL and MALT
lymphoma. A reduced expression of miR-182/96/183 was also
noted in cases of SMZL lacking the 7q32 deletion (Figure S1),
suggesting presence of other molecular mechanisms that down-
regulate the expression of these miRNAs. Together, these
findings suggest an association of these miRNA expression
changes with SMZL.
The normal cell counterpart of SMZL is unknown, so it is not
possible to directly compare miRNA expression between SMZL
and the cell of its origin. Several studies have investigated the
miRNome of normal B-cell subsets by expression microarrays and
shown variable expression of miR-182/96/183 among different B-
cell subsets, being expressed highly in the germinal centre B-cells,
but moderately in the naı¨ve and memory B-cells [18,19]
suggesting an important role of these miRNA in B-cell biology.
The findings of reduced expression of these miRNA in SMZL
relative to other lymphoma subtypes arising from various stages of
B-cell maturation suggest that these changes were lymphoma
associated events rather than reflection of differential expression
patterns between the normal cell counterparts of these lympho-
mas. By comparing with non-neoplastic splenic marginal zone B-
cells, Peveling-Oberhag et al also identified a number of miRNAs
showing significantly altered expression in SMZL, further impli-
cating a role of miRNA deregulation in the lymphoma pathogen-
esis [20].
Alteration in miRNA sequences is another mechanism
underlying miRNA mediated oncogenesis [21]. We carried out
sequence analyses of all the 6 miRNA in the MDR together with
miR-29a/29b1 polycistron that lies distal to the MDR in 23
SMZL, but found no evidence of somatic mutation. A single
nucleotide polymorphism (rs76481776, G106A) was seen in the
primary miR-182 sequence. The polymorphism was functional
since it affected the expression of miR-182 as well as its target
genes [22]. In line with this, analysis of the predicted secondary
structure of the miR-182 G106A variant using RNA-Fold (www.
rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) reveals that the GRA
substitution replaces a G:U wobble base pair with a stronger A:U
pair in the double strand stem and this also impacts on the
neighbouring base pairs close to the terminal overhangs (Figure
S3). This region of pri-miRNA is critical for DGCR8 binding
and subsequent accurate Drosha cleavage [23]. The substitution
may affect the pri-miR-182 processing, thus the level of its
expression. It is interesting to note that the miR-182 G106A
polymorphism was at variable frequencies among different
lymphoma subtypes investigated, and the frequencies of the
polymorphism in SMZL (20%) and FL (20%) were much higher
than that (12.7%) in a Spanish control population (n = 341)
studied so far [22], but the difference was not statistical
significant. Nonetheless, it remains to be investigated whether
any of the miRNA at 7q32 is the target of 7q deletion. This is
particularly enigmatic since the miR-182/96/183 polycistron
were frequently over-expressed and thought to act as oncogenes
in solid tumours [24–27]. However, the biological effect of
miRNA expression is cell type and context dependent, and miR-
182 has also been shown to act as a tumour suppressor in lung
cancer [28], and it remains a possibility that these miRNA may
be important in the pathogenesis of SMZL.
Coding Genes as Possible Candidate Targets of 7q
Deletion in SMZL
Among of the 37 coding genes within the MDR, 18 were
significantly under-expressed in SMZL with the 7q deletion in
comparison with those without the deletion. In 10 of these
genes, their reduced expression appeared to be associated with
epigenetic methylation as shown by integrated analyses of the
gene expression and methylation microarray data, suggesting
that promoter methylation may underpin their reduced expres-
sion. However, similar correlations were also seen in FL and
MCL. It remains to be investigated whether these correlations
are associated with lymphoma development or a common
feature of their normal cell counterparts. In view of lack of clear
evidence that pinpoints the genes likely targeted by the deletion,
we further searched for somatic mutations in a favourite
candidate gene IRF5, encoding a transcriptional factor activated
by the TLR signalling. IRF5 is critical for antiviral immunity
and functions as a tumour suppresser [12]. However, sequenc-
ing of all the coding exons of IRF5 in 49 cases of SMZL showed
no evidence of somatic mutation. The deletion polymorphism in
IRF5 exon 6 (rs60344245) found in SMZL was also seen at
comparable frequencies in other B-cell lymphomas and a
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normal control population from Germany [13]. There are a
number of SNPs in the IRF5 gene including several known
functional SNPs in both the transcriptional regulatory and
coding regions. Several haplotypes of these IRF5 variants were
associated with distinct risks to human lupus and Wegener’s
granulomatosis [13,29]. It remains to be investigated whether
any of the IRF5 haplotypes or SNPs is associated with
lymphoma development.
To help the identification of the target genes of 7q deletion in
SMZL, we searched the somatic mutation data in the COSMIC
(Catalogue of Somatic Mutations in Cancer) database (http://
www.sanger.ac.uk/genetics/CGP/cosmic/). The majority of the
coding genes within the 7q MDR in SMZL are somatically
mutated in human cancer although their incidence is relatively low
and the functional impact of these mutations is unknown (Table 1).
The somatic mutations in FAM71F1, FLNC, TNP03, AHCYL2,
CPA4 and MEST involves both missense and nonsense changes,
suggesting that these genes might be targeted for inactivation. Of
these genes, FLNC is particularly interesting since it is frequently
repressed at the transcriptional level by promoter methylation in
several human cancer types [30–33]. It remains to be investigated
whether FLNC, and/or any of the other genes in the 7q MDR are
the target of the deletion in SMZL. In view of the wide availability
of massive parallel sequencing, the time for this discovery will not
be too far in the near future.
In summary, our integrated analyses of 7q deletion by genomic,
expression and methylation profiling showed that the expression of
several genes within the MDR was significantly affected by the
deletion. Our sequencing analyses also excluded the possibility of
several potential candidate genes as the target of 7q deletion. The
data presented in this study provide valuable guidance for further
characterisation of 7q deletion.
Supporting Information
Figure S1 Comparison of miRNA expression between
SMZL, FL, MCL and MALT lymphoma by qRT-PCR.
miR-593, miR-129, miR-182, miR-96, miR-183, miR-335 are
within the MDR defined in this study, while miR-29a/29b1
polycistron is distal to the MDR. In general, the expression of
these mature miRNAs is lower in SMZL with 7q deletion than
those without the deletion, although not statistically significant
with the exception of miR-29a. In addition, the express of these
miRNA is also lower in SMZL than FL, MCL and MALT
lymphoma. SMZL = Splenic marginal zone lymphoma;
7q2= 7q32 deletion; 7q+= 7q32 intact; FL = Follicular lym-
phoma, MCL = Mantle cell lymphoma, MALT = MALT lym-
phoma.
(TIF)
Figure S2 A functional polymorphism (G106A substitu-
tion) in pri-miR-182. A: Sequencing shows presence of G106A
substitution in both SMZL and microdissected normal cells (the
intact splenic capsule); B: RNAFold analysis of the G106A
polymorphism shows stronger stem structure at the site of the
mutation. Coloured scale displays the predicted base pairing
probability; C: The predicted hairpin loop of pri-miR-182
showing the site of the polymorphism; D: Frequency of the
polymorphism in SMZL and other lymphomas. SMZL: splenic
marginal zone lymphoma; FL: follicular lymphoma; MCL: mantle
cell lymphoma; CLL: chronic lymphocytic leukaemia/lymphoma;
MALT: MALT lymphoma; TCL: peripheral T-cell lymphoma
not otherwise specified (PTCL-NOS); DLBCL: diffuse large B-cell
lymphoma; HCL: hairy cell leukaemia; LPL: lymphoplasmacytic
lymphoma.
(TIF)
Figure S3 Comparison of the expression of coding genes
in MDR between 7q deletion positive and negative
SMZL. Of these 38 genes within the MDR, 37 are represented
on the Affymetrix U133 Plus 2.0 array, and 18 of these genes
(TNPO3, KLHDC10, RBM28, NIPA, SND1, TSGA14, TMEM209,
UBE2H, NRF1, NAG8, ATP6V1F, CALU, AHCYL2, COPG2, HIG2,
TSPAN33, IMPDH1 and IRF5) are significantly under-expressed in
SMZL with 7q deletion in comparison with those without the
deletion (P,0.05).
(TIF)
Figure S4 Correlation of the expression and methyla-
tion levels of the genes within MDR in SMZL. Among the
37 genes which were represented in both the methylation and
Affymetrix expression arrays, CPA4, OPN1SW, NAG8, LRRC4,
CPA5, CPA2, TSGA13, CPA1, C7orf45 and NYD-SP18 were
consistently showed high levels of methylation but low gene
expression in each of the SMZL with 7 q deletion. The data shown
in this figure are the mean of normalised expression and
methylation values.
(TIF)
Figure S5 The IRF5 exon 6 in-frame 30 bp deletion
polymorphism (rs60344245) in SMZL. Panel A shows
examples of the SNP, panel B displays the frequency of the SNP
in SMZL, FL, MCL and DBLCL. There is no significant
difference in the frequency of the polymorphism (rs60344245)
among these lymphoma subtypes. SMZL: splenic marginal zone
lymphoma; FL: follicular lymphoma; MCL: mantle cell lympho-
ma; DLBCL: diffuse large B-cell lymphoma.
(TIF)
Table S1 Summary of SMZL used for CGH, gene
expression and epigenetic methylation microarray anal-
yses.
(XLS)
Table S2 Primers used for quantitative RT-PCR of
miRNAs.
(DOC)
Table S3 Primers used for genomic sequence analysis
of miRNA.
(DOC)
Table S4 Primers used for sequence analysis of IRF5.
(DOC)




The authors would like to thank Dr. Ian McFarlane, the Microarray
CoreLab, National Institute of Health Research, Cambridge Comprehen-
sive Biomedical Research Centre for his help in DNA sequencing.
Author Contributions
Conceived and designed the experiments: AJW MQD. Performed the
experiments: AJW RAH NZ QY YH EB RF EDM AD. Analyzed the data:
AJW RAH EB RF EDM AD MQD. Contributed reagents/materials/
analysis tools: HL JZ LdL PGI AW EB RF EDM AD. Wrote the paper:
AJW MQD.
Analyses of 7q Deletion in SMZL
PLOS ONE | www.plosone.org 8 September 2012 | Volume 7 | Issue 9 | e44997
References
1. Isaacson PG, Piris MA, Berger F, Swerdlow SH, Thieblemont C, et al. Splenic
B-cell marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe
ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumous of
Haematopoietic and Lymphoid Tissues. Lyon: International Agency for
Research on Cancer, 2008: 185–187.
2. Mateo M, Mollejo M, Villuendas R, Algara P, Sanchez-Beato M, et al. (1999)
7q31–32 allelic loss is a frequent finding in splenic marginal zone lymphoma.
Am J Pathol 154: 1583–1589.
3. Gruszka-Westwood AM, Hamoudi R, Osborne L, Matutes E, Catovsky D
(2003) Deletion mapping on the long arm of chromosome 7 in splenic lymphoma
with villous lymphocytes. Genes Chromosomes Cancer 36: 57–69.
4. Watkins AJ, Huang Y, Ye H, Chanudet E, Johnson N, et al. (2010) Splenic
marginal zone lymphoma: characterization of 7q deletion and its value in
diagnosis. J Pathol 220: 461–474.
5. Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, et al. (2012) Genomic
analysis of marginal zone and lymphoplasmacytic lymphomas identified
common and disease-specific abnormalities. Mod Pathol 25: 651–660.
6. Ruiz-Ballesteros E, Mollejo M, Mateo M, Algara P, Martinez P, et al. (2007)
MicroRNA losses in the frequently deleted region of 7q in SMZL. Leukemia 21:
2547–2549.
7. Expression profiling–best practices for data generation and interpretation in
clinical trials (2004 Nat Rev Genet 5: 229–237.
8. Pepper SD, Saunders EK, Edwards LE, Wilson CL, Miller CJ (2007) The utility
of MAS5 expression summary and detection call algorithms. BMC Bioinfor-
matics 8: 273.
9. Hamoudi RA, Appert A, Ye H, Ruskone-Fourmestraux A, Streubel B, et al.
(2010) Differential expression of NF-kappaB target genes in MALT lymphoma
with and without chromosome translocation: insights into molecular mechanism.
Leukemia 24: 1487–1497.
10. Sabbah C, Mazo G, Paccard C, Reyal F, Hupe P (2011) SMETHILLIUM:
spatial normalization method for Illumina infinium HumanMethylation
BeadChip. Bioinformatics 27: 1693–1695.
11. Pan LX, Diss TC, Peng HZ, Isaacson PG (1994) Clonality analysis of defined B-
cell populations in archival tissue sections using microdissection and the
polymerase chain reaction. Histopathology 24: 323–327.
12. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, et al. (2007) Role of IFN
regulatory factor 5 transcription factor in antiviral immunity and tumor
suppression. Proc Natl Acad Sci U S A 104: 3402–3407.
13. Wieczorek S, Holle JU, Muller S, Fricke H, Gross WL, et al. (2010) A
functionally relevant IRF5 haplotype is associated with reduced risk to
Wegener’s granulomatosis. J Mol Med (Berl) 88: 413–421.
14. Troen G, Nygaard V, Jenssen TK, Ikonomou IM, Tierens A, et al. (2004)
Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and
c-fos and the marginal zone B-cell transcription factor Notch2 in splenic
marginal zone lymphoma. J Mol Diagn 6: 297–307.
15. Thieblemont C, Nasser V, Felman P, Leroy K, Gazzo S, et al. (2004) Small
lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell
lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis.
Blood 103: 2727–2737.
16. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, Camacho FI, Algara P, et al.
(2005) Splenic marginal zone lymphoma: proposal of new diagnostic and
prognostic markers identified after tissue and cDNA microarray analysis. Blood
106: 1831–1838.
17. Bouteloup M, Verney A, Rachinel N, Callet-Bauchu E, Ffrench M, et al. (2012)
MicroRNA expression profile in splenic marginal zone lymphoma. Br J Haematol
156: 279–281.
18. Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, et al. (2009)
Differentiation stage-specific expression of microRNAs in B lymphocytes and
diffuse large B-cell lymphomas. Blood 113: 3754–3764.
19. Basso K, Sumazin P, Morozov P, Schneider C, Maute RL, et al. (2009)
Identification of the human mature B cell miRNome. Immunity 30: 744–752.
20. Peveling-Oberhag J, Crisman G, Schmidt A, Doring C, Lucioni M, et al. (2012)
Dysregulation of global microRNA expression in splenic marginal zone
lymphoma and influence of chronic hepatitis C virus infection. Leukemia.
21. Varol N, Konac E, Gurocak OS, Sozen S (2011) The realm of microRNAs in
cancers. Mol Biol Rep 38: 1079–1089.
22. Saus E, Soria V, Escaramis G, Vivarelli F, Crespo JM, et al. (2010) Genetic
variants and abnormal processing of pre-miR-182, a circadian clock modulator,
in major depression patients with late insomnia. Hum Mol Genet 19: 4017–
4025.
23. Winter J, Jung S, Keller S, Gregory RI, Diederichs S (2009) Many roads to
maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11:
228–234.
24. Bai AH, Milde T, Remke M, Rolli CG, Hielscher T, et al. (2011) MicroRNA-
182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma.
Acta Neuropathol.
25. Mihelich BL, Khramtsova EA, Arva N, Vaishnav A, Johnson DN, et al. (2011)
The miR-183–96–182 cluster is overexpressed in prostate tissue and regulates
zinc homeostasis in prostate cells. J Biol Chem.
26. Zhang L, Liu T, Huang Y, Liu J (2011) microRNA-182 inhibits the proliferation
and invasion of human lung adenocarcinoma cells through its effect on human
cortical actin-associated protein. Int J Mol Med 28: 381–388.
27. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, et al. (2011) miR-
182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to
PARP inhibitors. Mol Cell 41: 210–220.
28. Sun Y, Fang R, Li C, Li L, Li F, et al. (2010) Hsa-mir-182 suppresses lung
tumorigenesis through down regulation of RGS17 expression in vitro. Biochem
Biophys Res Commun 396: 501–507.
29. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, et al. (2007)
Three functional variants of IFN regulatory factor 5 (IRF5) define risk and
protective haplotypes for human lupus. Proc Natl Acad Sci U S A 104: 6758–
6763.
30. Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J, et al. (2011) Genomic and
epigenomic integration identifies a prognostic signature in colon cancer. Clin
Cancer Res 17: 1535–1545.
31. Vanaja DK, Ehrich M, Van den BD, Cheville JC, Karnes RJ, et al. (2009)
Hypermethylation of genes for diagnosis and risk stratification of prostate
cancer. Cancer Invest 27: 549–560.
32. Kim JH, Jung EJ, Lee HS, Kim MA, Kim WH (2009) Comparative analysis of
DNA methylation between primary and metastatic gastric carcinoma. Oncol
Rep 21: 1251–1259.
33. Imura M, Yamashita S, Cai LY, Furuta J, Wakabayashi M, et al. (2006)
Methylation and expression analysis of 15 genes and three normally-methylated
genes in 13 Ovarian cancer cell lines. Cancer Lett 241: 213–220.
Analyses of 7q Deletion in SMZL
PLOS ONE | www.plosone.org 9 September 2012 | Volume 7 | Issue 9 | e44997
